SEATTLE--(BUSINESS WIRE)--MitoPharm Corporation, Inc. (Pink Sheets:MTPM), released today published findings on the beneficial effects of Schisandrin B, the precursor of (-) Schisandrin B - a novel discovery by its founding shareholder Dr. Robert Ko - on protection against physical exercise-induced muscle injuries. MitoPharm believes that its products have the potential to play a significant role in addressing the aging concerns of the baby boomers, the heart-health and heart-diseases markets, and the segment of the population that is physically active. www.mitopharm.com
